These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9839116)

  • 1. Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
    Gorson DM
    Diabetes Care; 1998 Dec; 21(12):2190-1. PubMed ID: 9839116
    [No Abstract]   [Full Text] [Related]  

  • 2. [Qualitative study of proteinuria in diabetic nephropathy].
    Faure Nogueras E; Blasco Comenge MC; Guillén Martínez G
    An Med Interna; 1991 Jul; 8(7):333-5. PubMed ID: 1932490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
    Guerrero-Romero F; Rodríguez-Morán M; Paniagua-Sierra JR; García-Bulnes G; Salas-Ramírez M; Amato D
    Clin Nephrol; 1995 Feb; 43(2):116-21. PubMed ID: 7736673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy.
    Navarro JF; Mora C
    Diabetes Care; 1999 Jun; 22(6):1006-8. PubMed ID: 10372263
    [No Abstract]   [Full Text] [Related]  

  • 5. [Proteinuria in diabetes mellitus--a prognostic indicator even in type II?].
    Janka HU
    Dtsch Med Wochenschr; 1987 Sep; 112(38):1443-4. PubMed ID: 3622291
    [No Abstract]   [Full Text] [Related]  

  • 6. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
    Navarro JF; Mora C; Muros M; García J
    J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
    J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proteinuria in diabetics].
    Vörös P; Kammerer L; Miltényi M; Körner A; Németh C
    Orv Hetil; 1985 Sep; 126(38):2327-31. PubMed ID: 4047637
    [No Abstract]   [Full Text] [Related]  

  • 9. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and treatment of diabetic renal disease.
    Clement JD; Cottiero RA
    Med Health R I; 1998 Nov; 81(11):348-9. PubMed ID: 15580788
    [No Abstract]   [Full Text] [Related]  

  • 11. Adequate vascular repair is relevant to improving renal perfusion and function following vasodilators in normoalbuminuric type 2 diabetic nephropathy.
    Futrakul N; Futrakul P
    Am J Kidney Dis; 2009 Sep; 54(3):583-4. PubMed ID: 19700066
    [No Abstract]   [Full Text] [Related]  

  • 12. Exercise induced proteinuria as an early indicator of diabetic nephropathy.
    Agarwal RP; Thanvi I; Vachhani G; Kochar DK; Rastogi A
    J Assoc Physicians India; 1998 Sep; 46(9):772-4. PubMed ID: 11229244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Microalbuminuria in diabetic patients].
    Forsblom C; Groop L
    Duodecim; 1995; 111(15):1463-9. PubMed ID: 9244702
    [No Abstract]   [Full Text] [Related]  

  • 14. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy.
    Solerte SB; Fioravanti M; Patti AL; Schifino N; Zanoletti MG; Inglese V; Ferrari E
    Acta Diabetol Lat; 1987; 24(3):229-39. PubMed ID: 3687315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression.
    Popławska-Kita A; Mierzejewska-Iwanowska B; Szelachowska M; Siewko K; Nikołajuk A; Kinalska I; Górska M
    Diabetes Metab Res Rev; 2008; 24(4):310-7. PubMed ID: 18273859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy.
    Sharma K; Lee S; Han S; Lee S; Francos B; McCue P; Wassell R; Shaw MA; RamachandraRao SP
    Proteomics; 2005 Jul; 5(10):2648-55. PubMed ID: 15984045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephropathy in type 2 diabetes.
    Mora C; Garcia J; Navarro JF
    N Engl J Med; 2000 Feb; 342(6):441; author reply 442. PubMed ID: 10681230
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus.
    Awadallah SM; Saleh SA; Abu Shaqra QM; Hilow H
    J Diabetes Complications; 2008; 22(6):384-8. PubMed ID: 18413152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microalbuminuria prevalence study in hypertensive type 2 diabetic patients in Malaysia.
    Kong NC; Chia YC; Khalid BA; Juwita S; Samiah Yasmin AK; Yap LY; Norlaila M; Menon J; Tan C; Fung YK;
    Med J Malaysia; 2006 Oct; 61(4):457-65. PubMed ID: 17243524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences.
    Gall MA
    Dan Med Bull; 1997 Nov; 44(5):465-85. PubMed ID: 9408734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.